Business Context and Reporting Period
Company: Krystal Biotech, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: August 3, 2026
Reporting Period: Quarter ended June 30, 2026
This filing announces the financial results for the second quarter of 2026. The detailed results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the referenced Exhibit 99.1 (Press Release) and are not explicitly stated within the body of this Form 8-K.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: The filing serves as a notification of the results announcement. Specific management commentary, guidance, or outlook is contained within the attached press release (Exhibit 99.1).
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt. The filing includes a standard disclaimer stating that the financial results information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated into other registration statements unless expressly referenced.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for the quarter ended June 30, 2026.
- Verify year-over-year and quarter-over-quarter growth rates in the attached press release.
- Check for any updated forward-looking guidance or clinical trial milestones mentioned in the press release.
- Confirm the status of the company's cash position and burn rate as detailed in the full financial disclosure.